Background: End-stage heart failure with idiopathic dilated cardiomyopathy (DCM) has no therapeutic options other than heart transplantation. We investigated whether exogenous insulin-like growth factor-1 (IGF-1) could improve cardiac function and symptoms in end-stage DCM patients on the waiting list for heart transplantation.
INTRODUCTION
Demand for donor hearts has doubled in recent years, while supply of hearts was decreasing [1] . Thus, the waiting time before transplantation among heart-transplant recipients has increased to more than one year [1] . Mechanical circulatory support is used for bridge to transplant or bridge to recovery. We are seeking less invasive and less expensive circulatory support measure for bridge to transplant or recovery.
In randomized studies for dilated cardiomyopathy (DCM), growth hormone (GH) had neutral effects in cardiac function and symptoms [2, 3] . In those studies, however, the level of insulinlike growth factor-1 (IGF-1) induced by GH rather than GH itself affected the improvement in cardiac function [4, 5] . IGF-1 has proliferating, inotropic, vasodilatory, and anti-apoptotic effects in cardiovascular system [6] [7] [8] [9] [10] . Acute injection of IGF-1 into healthy and heart failure subjects resulted in inotropic effects [11, 12] . Moreover, an association between myocardial IGF-1 gene expression with recovery from ventricular assist device was reported [13] . However, the effects of chronic administration of IGF-1 on failing heart remained unclear. Thus, we investigated feasibility and effectiveness of a three-month treatment with recombinant IGF-1 on eight hospitalized patients with end-stage DCM, who were on the waiting list for heart transplantation.
METHODS

Study Protocol
The study was conducted according to the declaration of Helsinki and was approved by the institutional review boards (Approval number #12-13). After approval by the institutional ethics committee, consecutive eight patients were enrolled into the study. Eligibility requirements were as follows: 1) diagnosis of DCM based on the definition of the World Health Organization/ International Society and Federation of Cardiology Task Force [14] , confirmed by cardiac catheterization and endomyocardial biopsy; 2) New York Heart Association (NYHA) functional class III or IV and left ventricular (LV) ejection fraction (EF) less than 30% despite of optimal treatment including left ventricular assist device (LVAD); and 3) registration in the Japan Organ Transplant Network. Exclusion criteria were as follows: 1) acute or unstable stage of heart failure; 2) heart failure due to primary ischemic or valvular heart diseases, or myocarditis; 3) malignancy; 4) tendency to hypoglycemia due to various disorders including diabetes mellitus; 5) renal and/or hepatic dysfunctions; 4) disorders in endocrine system including GH and IGF-1; and 5) infectious or inflammatory diseases. Baseline characteristics of the patients are reported in Table (1) . As shown in Table (1) , all the patients received optimal and maximal conventional medications for refractory heart failure. Of note, effective dose of carvedilol for Japanese patients with heart failure was 5 to 20 mg in MUCHA study [15] , which was less than half of that in MOCHA study [16] in the United States. None of them had abnormal levels of serum GH and IGF-1. After written informed consent was obtained, recombinant IGF-1 was given to eight patients for three months in addition to the other previous medications. Treatments other than IGF-1 were not changed during the three-month injection period. IGF-1, injected once a day at 0900 h after breakfast, was titrated weekly from 0.05 mg/kg up to 0.3 mg/kg with close monitoring of blood glucose in order to avoid hypoglycemia. Then, fasting blood glucose was stable during the study (Table 3) . We set the dose ranging from 0.05 to 0.3mg/kg, according to the approved dose for insulin receptor Subcutaneous abnormality or Laron dwarfism in Japan. The final dose was determined not to induce hypoglycemia. Final doses ranged from 0.15 to 0.30 mg/ kg (median 0.25 mg/kg).
Cardiac Function, Exercise Capacity and Blood Neurohumoral Factors
Before the beginning of the IGF-1 treatment, at its end, and three months after its discontinuation, the NYHA functional class and daily life activity assessed by the specific activity scale questionnaire [17] were determined in all patients. At the same time points, ECG, cardiac catheterization, echocardiography, magnetic resonance imaging (MRI), cardiopulmonary exercise test, high-resolution ultrasound flow-mediated dilatation (FMD) of the brachial artery, and coronary flow velocity reserve (CFVR) under sinus rhythm assessed by transthoracic Doppler echocardiography were conducted. For a patient with LVAD, enhanced electron beam CT was performed instead of MRI [18] . Also at those time points, the estimation of lean body mass by dual-energy X-ray absorptiometry (Lunar DPX-L) was available in five patients. Likewise, blood levels before breakfast of the following substances were measured: standard laboratory chemistry, complete blood counts, IGF-1 (Daiichi Radioisotope), free IGF-1 [19] (Mitsubishi Kagaku Iatron Inc.), GH (Daiichi Radioisotope), IGF binding protein-3 (IGFBP-3) (Diagnostic Systems Laboratories), atrial natriuretic peptide (ANP) (Shionogi), brain natriuretic peptide (BNP) (Shionogi), epinephrine, norepinephrine, renin activity, aldosterone, angiotensin II, cyclic GMP (Cayman Chemical), nitrite/nitrate (HPLC autoanalyzer, Eicom), interleukin-6 (R&D Systems), and tumor necrosis factor-α (TNF-α) (R&D Systems). Because IGF-1 stimulates proliferation of putative endothelial progenitor cells (EPC) such as CD34 + cells [20] , circulating CD34 + and CD133 + cells were counted with standard flow cytometry method [21] .
Histology of Myocardial Biopsies
Myocardial biopsies were obtained from the right ventricular side of the septum at the abovementioned three-time points. Five-micrometer-thick paraffin embedded sections were stained and examined with microscopic digital camera in random order by observers who were blinded to the sample source and date of acquisition. Myocyte diameter and percent fibrosis area were determined by a digital image analyzer according to the method described previously [22] . Immunohistochemical staining were performed using an anti-human IGF-I monoclonal antibody (Upstate Biotechnology), anti-human IGF-1 receptor (IGF-1R) monoclonal antibody (R&D Systems), anti-human phosphorylated Akt monoclonal antibody (Cell Signaling) and anti-human TNF-α monoclonal antibody (Santa Cruz). The myocardial contents of IGF-1, IGF-1R, phosphorylated Akt kinase and TNF-α were determined by quantitative analysis of stained area using Win-ROOF (Mitani) according to the method by TorreAmione et al. [23] , based on Matsuo's method [24] . Terminal dUTP nick-end labeling (TUNEL) staining was performed with ApopTag Kit (Chemicon International) with counterstaining by methyl green. Cardiomyocytes in 60 random high-power fields (x400) per patients were counted.
Myocardial Gene Expressions
Total RNA was prepared from biopsy samples using an RNeasy Fibrous Tissue Kit (QIAGEN). From these samples, mRNA was then amplified by T7 RNA polymerase. Complementary DNA was produced by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) using a QuantiTect RT-PCR Kit (QIAGEN) and by a Prism 7700 Sequence Detector (Applied Biosystems) [25] . To correct for the efficiency of cDNA synthesis, measured mRNA amounts were divided by the amount of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) mRNA as an internal standard. We used the following sense and antisense primers (Takara Bio Inc., Otsu): AMD 100 [11] AMD 100 [23] AMD 100 [27] AMD 150 [30] AMD 100 [12] MEX 100 [27] DIG DGX 0.125 [34] DGX 0.125 [12] DGX 0.25 [26] DGX 0.125 [23] DGX 0.125 [27] DGX 0.125 [30] DGX 0.125 [15] Oral INT PMB 2. 5'-TTCCAGATGTCAGGGATCAAAG-3' for TNF-α (89bp); 5'-CCT-GCACCACCAACTGCTTAG-3' and 5'-GCCATCACGCCACAGTTTC-3' for GAPDH (146bp). Sequences of amplified fragments were confirmed by DNA sequencing.
Statistics
Data are presented as mean± SD unless indicated otherwise. Changes in variables between the baseline and the end of treatment, and the baseline and the three-month follow-up were evaluated by either paired t test or Wilcoxon signed-rank test, as appropriate. The correlation of the changes in variables was assessed by Pearson or Spearman correlation coefficient, as appropriate. A value of p<0.05 was considered significant.
RESULTS
Symptoms and Cardiac Function
None of the patients died or underwent heart transplantation during the treatment and the follow-up period. One patient, whose cardiac performance responded to the treatment, had an unexpected relapse of heart failure after completion of treatment. His follow-up study was not conducted because of unstable conditions. Symptoms and physiological parameters of the patients at baseline, at the end of treatment, and at the threemonth follow-up are described in Table ( 2) and Figure 1 . NYHA functional class and daily life activity were significantly improved at the end of treatment, and remained improved at the follow-up. Blood pressure, heart rate, number of ventricular arrhythmias, and cardiothoracic ratio did not change significantly during the entire study. Body weight and lean body mass were increased after treatment and then returned to baseline levels at the followup.
Five out of eight patients (Patients 1-4 and 8) experienced symptomatic hypoglycemia just before lunch during the titerating period of IGF-1. The final dose was determined not to induce hypoglycemia. Neither consciousness loss nor faintness was reported. Patients 2 and 6 had transient increases in hepatic transaminases, which were normalized within two weeks with no interruption of IGF-1 injection. In all the patients, blood levels of IRI, CPR, ACTH, FSH, LH, T 4 , T 3 , CEA, AFP, CA19-9, BCA225, and PA were not changed during the IGF-1 treatment.
Catheter-derived cardiac index was increased, and LV end-diastolic pressure and systemic vascular resistance index were decreased significantly at the end of treatment. At the end of treatment, echocardiographic fractional shortening and posterior wall thickness increased significantly, without further deterioration of diastolic function, which was determined by E/A and deceleration time of E wave ( Table 2) . Likewise, LVEF and LV mass index (LVMI), determined by MRI, were significantly increased. However, ECG showed no significant changes in QRS voltage index for hypertrophy (SV 1 +RV 5 ). The percent changes in LVEF correlated with the percent changes in LVMI (p=0.043, r=0.72). Variables of exercise capacity such as peak oxygen consumption, anaerobic threshold, exercise duration, and peak workload were significantly increased compared to baseline. FMD and CFVR were also increased significantly. The percent changes in FMD correlated with the percent changes in peak oxygen consumption (p=0.021, r=0.79). At three-month followup, those physiological parameters, except for functional class, daily life activity, wall thickness and FMD, had returned to baseline levels (Table 2 and Figure 1 ).
Blood Neurohumoral Factors
At the end of treatment, serum IGF-1 and free IGF-1 was increased significantly from their baseline levels, to which they had returned at the follow-up (Table 3 ). The percent changes in free IGF-1 level correlated with the percent changes in LVMI (p=0.028, r=0.83) and LVEF (p=0.010, r=0.976) during the three-month treatment. GH and IGFBP-3 levels were decreased significantly from their baseline levels, to which they had returned at the follow-up. At the same time points, levels of norepinephrine, ANP, BNP, IL-6, and TNF-α were decreased significantly. Renin, aldosterone and angiotensin II levels did not change. Cyclic GMP and nitrite/nitrate levels were increased significantly. The percent changes in serum cyclic GMP (p=0.044, r=0.76), nitrite/nitrate (p=0.032, r=0.81), IL-6 (p=0.044, r=-0.76) and TNF-α (p=0.017, r=-0.91) levels correlated with the percent changes in FMD. An index of insulin resistance, HOMA-IR, improved at the end of treatment, which may relate to endothelial function. Putative endothelial progenitor cells were increased, which may relate to the improvement in FMD.
At the follow-up, those neurohumoral parameters, except for BNP, cyclic GMP and nitrite/nitrate had returned to their baseline levels.
Quantification of Myocardial Biopsies
Myocyte diameter was increased significantly at the end of treatment (Table 4) . Area of fibrosis did not change during the Table 4 , myocyte diameter increased after treatment and was kept equal at the follow-up, while aniline blue fibrotic area in Masson's trichrome stain did not change. IGF-1 positive area, IGF-1R positive area and P-Akt positive area also increased after treatment and was kept equal at the follow-up. TNF-α positive area decreased and then restored to the baseline level. The number of TUNEL positive cells did not change during the study. Figure (3) shows magnetic resonance imaging of ventricular structure and changes in counts of putative circulating EPC (circulating peripheral CD34+ and CD133+ cells in Table 3 ).
Removal from Transplant Waiting List and Recurrence of Heart Failure
Patient #1 was removed from the list of the Japan Organ Transplant Network, because the improvement in cardiac function was great enough for removal at the end of treatment (EF 18 to 29 %, BNP 53 to 16 pg/mL). LVAD was removed from Patient #3 after treatment, because the improvement in cardiac function was great enough for removal (EF 8 to 24 %, BNP 188 to 50 pg/mL). At the follow-up, he was removed from the list of the Japan Organ Transplant Network, because he was stable even after the discontinuation of mechanical and inotropic support (EF 24 to 38 %, BNP 50 to 99 pg/mL). All patients except Patient #6 were discharged from the hospital after the treatment.
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The patient #8 was discharged with stable condition eight days after cessation of IGF-1. Seventy-two days after cessation of IGF-1, the patient re-admitted hospital for recurrence of heart failure. Eighty-seven days after cessation of IGF-1, the patients got cardiogenic shock even with intravenous catecholamine. Intra-aortic balloon pumping was not effective for hemodynamic support. Next day, the patient received LVAD implantation. His three-month follow-up study was not conducted because of unstable hemodynamic conditions.
DISCUSSION
Main findings of the study were 1) three-month administration of recombinant IGF-1 was safe and feasible; 2) symptom of heart failure, daily life activity, ventricular contractility, ventricular mass, exercise and vasodilatory capacity were improved; 3) A part of improvements remained even at the three-month followup; 4) Two out of eight patients were removed from the waiting list because of improvement in cardiac function.
Left ventricular Hypertrophy and Functional Improvement
In the present study, exogenous IGF-1 tripled the basal IGF-1 level at the end of treatment. Simultaneously, endogenous GH and IGFBP-3 levels were suppressed. In the previous GH studies, serum level of IGF-1 induced by exogenous GH correlated with LV mass (3) and LVEF (5) . The present study showed the correlation between the changes in LVEF and LVMI during the IGF-1 treatment, suggesting that induction of cardiac hypertrophy partly underlies the inotropic effects of IGF-1 [8, 11, 12] . Echocardiographic diastolic indices and myocardial fibrosis did not deteriorate during the study. Moreover, the changes in myocardial diameter at the end of treatment correlated with the changes in LVMI, suggesting LV hypertrophy induced by IGF-1 was primarily of myocardial, and not fibrotic origin. Thus, the LV hypertrophy observed here upon IGF-1 treatment might constitute physiological rather than pathological hypertrophy, in corroboration with previous studies [7, 26] .
Myocardial staining area and gene expression of IGF-1 were up regulated at the end of treatment in spite of tremendous elevation of circulating IGF-1. Although exogenous IGF-1 downregulates IGF-1 receptors in physiological situation [27] , we found the up-regulation of myocardial staining area and gene expression of IGF-1 receptor at the end of treatment. Underlying molecular mechanisms need to be elucidated. Nevertheless, accompaniment of the myocardial staining of phosphorylated Akt kinase, which is in the downstream of IGF-1 receptor, might suggest the IGF-1 signal transduction was initiated by treatment in the diseased myocardium. Further, Akt kinase plays a role in physiological myocardial hypertrophy [7, 26] . Recent studies have suggested that Akt kinase played a pivotal role in the suppression of myocardial apoptosis induced by ischemia/ reperfusion, oxidative stresses, and heart failure [8, 10, 28] .
We do not know the exact mechanism of loss of improvements at the follow-up, which was obtained by IGF-1. This may relate to myocyte degradation in dilated cardiomyopathy. Apoptosis, ubiquitin-proteasome proteolysis, lysosomal cathepsin hydrolysis, calcium-dependent calpain digestion and autophagy may be involved in myocardial degradation in dilated cardiomyopathy. IGF-1 hypertrophies cardiac and skeletal myocytes and interrupts the myocyte proteolysis [25] . The balance between myocardial hypertrophy and atrophy determines the left ventricular mass and hence ejection fraction. In dilated cardiomyopathy, myocardial degradation processes may not be completely interrupted with exogenous IGF-1.
Pro-inflammatory Cytokines and Apoptosis
Activation of inflammatory cytokines, such as TNF-α and IL-6, has been associated with more severe symptoms and shortened survival in heart failure [29, 30] . TNF-α has been implicated as one of the major modulators of heart failure and has been an important therapeutic target [31, 32] . Previous experiments have demonstrated that TNF-α inhibits the transcriptional response to growth hormone [33] and suppresses the expression of IGF-1 and its receptor [34] . On the other hand, IGF-1 is known to be an anti-inflammatory agent that down-regulates pro-inflammatory cytokines [35] [36] [37] [38] [39] [40] . A very recent study reported that IGF-1 may interrupt the signaling between TNF-α and pro-apoptotic factors [41] . In the present study, serum IL-6 and TNF-α levels along with the myocardial staining and gene expression levels of TNF-α decreased at the end of treatment. Those anti-inflammatory effects of exogenous IGF-1 might be relevant to up-regulations of intrinsic IGF-1/IGF-1R system in the diseased myocardium.
Exercise tolerance and Peripheral Vessels
Endothelial dysfunction including impairment of endothelial nitric oxide (NO) synthesis is seen in heart failure and may contribute to the exercise intolerance and end-organ dysfunction of chronic heart failure [42] [43] [44] [45] [46] [47] [48] [49] . IGF-1 improves endothelial function via an enhancement of endothelial NO synthase activity [11, 50] . These effects of IGF-1 on endothelial function may in part underlie its therapeutic potential in chronic heart failure patients. In the present study, the increases in serum cyclic GMP and nitrite/nitrate levels, and the decreases in serum IL-6 and TNF-α levels accompanied with the improvement in FMD. The improvement in FMD might affect the improvement in peak oxygen consumption. Lastly, the increase in the lean body mass might indicate improvement of skeletal muscle force, e.g. average grip force, which may give rise to the observed improvement in exercise capacity (Table 2) .
BNP at the follow-up was still lower than the baseline value. FMD was still improved at the follow-up. Pro-inflammatory cytokines such as TNF-α and IL-6 tended to be lower than baseline values (p=0.063). Sustained improvement of those humoral and vascular factors might keep NYHA functional class or subjective symptom less severe than that in the baseline, even though peak VO 2 returned to baseline at the follow-up.
LIMITATIONS AND CONCLUSIONS
We acknowledge limitations of our study, the foremost of which are the small sample size and lack of randomization and placebo controls. It is ethically hard to administer placebos to end stage patients on the waiting list. This small study needs to be interpreted cautiously. Further, only one female is present in the present study to see any gender differences plays a role in IGF-1 treatment for bridge to recovery/transplant. This can also
In the present study, BNP levels may look rather low for advanced heart failure. Shionogi assay that we used for BNP measurement gives number that can be considerably lower than those from Triage BNP assay (Biosite Diagnostics, USA) [51] . Furthermore, according to exclusion criteria for acute or unstable stage of heart failure, the patients with severe but stable heart failure were recruited for the present study. Stable heart failure may have lower BNP value than unstable heart failure does.
One patient, whose cardiac performance responded to the treatment, had an unanticipated severe relapse and needed LVAD. Nonetheless, we feel that this study demonstrates that short-term recombinant IGF-1 may improve cardiac function and daily life activity of the patients with end-stage DCM. Reports on the relations between IGF-1 and longevity [52] , cancer [53] and atherosclerosis [54] are accumulating. Long-term and excessive IGF-1 may induce hypertrophic cardiomyopathy and heart failure [55] . Thus, therapeutic usage of IGF-1 should be conducted carefully for a selective subgroup of cardiomyopathy with appropriate dose and duration.
In immediate previous publications, translational studies not just only for IGF-1, but also for other growth factors relevant to heart failure have been reported [56] [57] [58] [59] .
Collectively, our data suggest that three-month IGF-1 therapy is safe and feasible in the patients on the waiting list for heart transplantation with end-stage DCM, and furthermore, is associated with improved cardiac function and symptoms [60] [61] [62] [63] [64] [65] . Thus, IGF-1 therapy might be worth pursuing as a novel method for bridge to transplant or recovery for the patients with end-stage heart failure with idiopathic DCM.
